Sangmin Lee, MD, discusses a potential way to overcome resistance to venetoclax in acute myeloid leukemia.
Sangmin Lee, MD, a physician at Weill Cornell Medicine, discusses a potential way to overcome venetoclax (Venclexta) resistance in acute myeloid leukemia (AML).
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More